by Riley Nolan | Nov 17, 2021 | Featured, News
PROVIDENCE, RI, November 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication of three papers focusing on malaria vaccine efficacy, part of a collaboration with Leidos, the University of Georgia Center for Vaccines and Immunology, the University...
by Riley Nolan | Jul 28, 2021 | Featured, Thinking Out Loud -Blog
(Delta) Variants at the Gates Been to the Disco lately? In the Netherlands, dancing is fueling a new wave of COVID infections. You can’t ignore the rise of COVID-19 cases globally after the Delta variant began circulating widely in June. Our hearts go out to...
by Riley Nolan | Jul 6, 2021 | Featured, News
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...
by Riley Nolan | Jun 14, 2021 | Featured, Thinking Out Loud -Blog
The Curious Case of HCP-driven Immunogenicity The FDA briefly “paused” the Johnson & Johnson adenovirus-based COVID-19 vaccine in April, and the AstraZeneca vaccine (also adenovirus-based) was in the news as early as March. Both of these pauses were to...
by Riley Nolan | Jun 10, 2021 | Featured, Thinking Out Loud -Blog
EpiVax has been busy helping our clients, and the research flywheel is spinning faster than ever. We needed more talented folks to pitch in! So far we’ve brought on six wonderful team members in 2021, with more to come soon! Learn more about our new folks below,...